Clinical Trial Update: Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating AK112 in combination with chemotherapy and/or Olaparib for platinum-sensitive ovarian cancer; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer
• Platinum-sensitive Ovarian Cancer

Drugs mentioned

• AK112
• Lynparza (olaparib)

Snippet

Sponsor: Akeso | Conditions: Platinum-sensitive Ovarian Cancer | Phase 2 | Status: RECRUITING